Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

29.66 +1.17 (+4.11%)
Streaming Delayed Price Updated: 1:41 PM EDT, Sep 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,780,154
Open 28.60
Bid (Size) 29.63 (1)
Ask (Size) 29.70 (2)
Prev. Close 28.49
Today's Range 28.33 - 31.65
52wk Range 8.790 - 42.20
Shares Outstanding 41,969,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Cassava Sciences Stock Dived by Almost 11% Today
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
Via The Motley Fool
Cassava Sciences Unusual Options Activity
Via Benzinga

Performance

YTD
+32.29%
+32.29%
1 Month
+3.31%
+3.31%
3 Month
+144.32%
+144.32%
6 Month
+46.18%
+46.18%
1 Year
+76.55%
+76.55%

More News

Read More
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Market Whales and Their Recent Bets on SAVA Options
Via Benzinga
What's Going On With Cassava Sciences Today?
Via Benzinga
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cassava Sciences Resolves SEC Investigation
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Via Benzinga
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
(SAVA) - Analyzing Cassava Sciences's Short Interest
Via Benzinga
Cassava Sciences Names Rick Barry as Chief Executive Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Via MarketBeat
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
Via InvestorPlace
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences News: Why Is SAVA Stock Trending Today?
Via InvestorPlace
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Shares Are Trading Higher Today: What You Need To Know
Via Benzinga
Get Your Money Out of These 3 Healthcare Stocks ASAP
Via InvestorPlace
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Via Benzinga
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
From Cassava Sciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.